Edwards Lifesciences CorpEW

EW current price
$73.32-4.66%

Capital at risk.

1W
+2.10%
1M
+9.55%
3M
+5.71%
6M
-15.60%
1Y
-4.66%
MAX
+239.13%
About Edwards Lifesciences Corp
Ticker
info
EW
Trading on
info
NYSE
ISIN
info
US28176E1082
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Bernard J. Zovighian
Headquarters
info
One Edwards Way, Irvine, CA, United States, 92614
Employees
info
19,800
Website
info
edwards.com
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Metrics
BasicAdvanced
Market cap
info
$43.6B
P/E ratio
info
28.56
EPS
info
$2.59
Dividend Yield
info
0.00%
Beta
info
1.12
Forward P/E ratio
info
30.49
EBIDTA
info
$2.05B
Ex dividend date
info
-
Price & volume
Market cap
info
$43.6B
Average daily volume
info
4.7M
90-day return
info
5.71%
30-day return
info
9.55%
7-day return
info
2.10%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
28.56
Forward P/E
info
30.49
PEG ratio
info
6.78
Trailing P/E
info
28.56
Price to sales
info
6.91
Price to book
info
4.56
Earnings
EPS
info
$2.59
EPS estimate (current quarter)
info
$0.64
EPS estimate (next quarter)
info
$0.62
EBITDA
info
$2.05B
Revenues (TTM)
info
$6.31B
Revenues per share (TTM)
info
$10.50
Technicals
Beta
info
1.12
52-week High
info
$96.12
52-week Low
info
$58.93
50-day moving average
info
$68.95
200-day moving average
info
$78.76
Short ratio
info
1.8
Short %
info
1.47%
Management effectiveness
ROE (TTM)
info
19.14%
ROA (TTM)
info
10.65%
Profit margin
info
65.86%
Gross profit margin
info
$4.3B
Operating margin
info
29.11%
Growth
Quarterly earnings growth (YoY)
info
716.10%
Quarterly revenue growth (YoY)
info
8.90%
Share stats
Outstanding Shares
info
590M
Float
info
584M
Insiders %
info
0.91%
Institutions %
info
85.92%
Analyst Insights & forecasts
info

41% Buy

59% Hold

0% Sell

Based on information from 32 analysts.

Average price target

info
$78.99
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.64
$0.64
-
Q4 • 23Beat
$0.66
$0.64
3.13%
Q1 • 24Beat
$0.70
$0.69
1.45%
Q2 • 24Beat
$0.67
$0.64
4.69%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$1.39B
$366M
26.43%
Q2 • 24
$1.35B
$3.07B
226.73%
Q3 • 24
2.27%
738.33%
757.83%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$10.1B
$2.59B
25.69%
Q2 • 24
$13B
$3.36B
25.90%
Q3 • 24
28.44%
29.49%
0.82%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$372M
$125M
$-96.6M
$286M
Q2 • 24
$352M
$2.7B
$-977M
$320M
Q3 • 24
5.30%
2,064.82%
911.08%
11.81%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

0.02

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Edwards Lifesciences Corp share?
Collapse

Edwards Lifesciences Corp shares are currently traded for $73.32 per share.

How many shares does Edwards Lifesciences Corp have?
Collapse

Edwards Lifesciences Corp currently has 590M shares.

Does Edwards Lifesciences Corp pay dividends?
Collapse

No, Edwards Lifesciences Corp doesn't pay dividends.

What is Edwards Lifesciences Corp 52 week high?
Collapse

Edwards Lifesciences Corp 52 week high is $96.12.

What is Edwards Lifesciences Corp 52 week low?
Collapse

Edwards Lifesciences Corp 52 week low is $58.93.

What is the 200-day moving average of Edwards Lifesciences Corp?
Collapse

Edwards Lifesciences Corp 200-day moving average is $78.76.

Who is Edwards Lifesciences Corp CEO?
Collapse

The CEO of Edwards Lifesciences Corp is Bernard J. Zovighian.

How many employees Edwards Lifesciences Corp has?
Collapse

Edwards Lifesciences Corp has 19,800 employees.

What is the market cap of Edwards Lifesciences Corp?
Collapse

The market cap of Edwards Lifesciences Corp is $43.6B.

What is the P/E of Edwards Lifesciences Corp?
Collapse

The current P/E of Edwards Lifesciences Corp is 28.56.

What is the EPS of Edwards Lifesciences Corp?
Collapse

The EPS of Edwards Lifesciences Corp is $2.59.

What is the PEG Ratio of Edwards Lifesciences Corp?
Collapse

The PEG Ration of Edwards Lifesciences Corp is 6.78.

What do analysts say about Edwards Lifesciences Corp?
Collapse

According to the analysts Edwards Lifesciences Corp is considered a hold.

Edwards Lifesciences Corp news